Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016

From both a regulatory and a clinical point of view, the main goal of any anticancer treatment is to allow patients to live longer and/or to live better [1]. Although appropriate end points in randomized controlled trials (RCTs) depend on the clinical setting, experimental treatments should ideally demonstrate a tangible clinical benefit for patients [2].